Swissmedic approves indication extension for Spikevax vaccine (previously COVID-19 Vaccine Moderna) for 12- to 17-year-olds
Bern, 9.8.2021 - Swissmedic has carefully examined the application from Moderna Switzerland GmbH for the indication extension and has extended the temporary authorisation for the Spikevax COVID-19 vaccines from Moderna for the prevention of the coronavirus disease in adolescents aged 12 to 17.